Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Xenon versus sevoflurane crossover comparison of cardiac performance during CABG surgery
NL-OMON31231Not yet recruiting
- Sponsor
- Erasmus MC
- Start
- Oct 2007
- Modality
- Small Molecules, Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Randomised, single-blind trial of xenon and sevoflurane in coronary arteriosclerosis (2 arms), sponsored by Erasmus MC. Primary endpoints: Change in cardiac performance, Cardiac function index and 1 more. Planned start Oct 2007; status: not yet recruiting.
02
Drugs
xenonsevoflurane
03
Conditions
coronary arteriosclerosis
Beyond the preview
Go deeper on NL-OMON31231.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON31231.